收藏切换
Analysis of different modes of early resolution mechanism of patent disputes for biologics
收藏切换
Xiu WANG1, Xuefang YAO2, Jinxi DING1, 3, *
World Clinical Drug | 2022, 43(11) : 1387 - 1392
Less
收藏切换
World Clinical Drug | 2022, 43(11): 1387-1392
• Recommendation •
Analysis of different modes of early resolution mechanism of patent disputes for biologics
Full
Xiu WANG1, Xuefang YAO2, Jinxi DING1, 3, *
Affiliations
  • 1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
  • 2.School of Health Economics and Management, Jiangsu Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China
  • 3.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
Published: 2022-11-10 doi: 10.13683/j.wph.2022.11.001
Outline
收藏切换

China has initially established early resolution mechanism of patent disputes (ERMPD) for biologics, but it is not yet complete. On the basis of clarifying the definition, function, type of the mechanism and content of typical national mechanism, this paper discusses the influencing factors of mode selection, so as to provide references for China to improve the ERMPD for biologics in the future. The present complete ERMPD for biologics can be divided into “soft linkage mode” and “hard linkage mode”. The model selection affected by factors such as mode function, industrial development, patent protection features, and international trade strategy. It is suggested that when improving the ERMPD for biologics in the future, China should combine the above factors and choose an institutional model that is more suitable for its national conditions.

biologic product  /  patent dispute  /  mechanism for early resolution  /  model selection  /  hard linkage  /  soft linkage
王秀, 姚雪芳, 丁锦希. 浅析生物制品专利纠纷早期解决机制的不同模式. 世界临床药物, 2022 , 43 (11) : 1387 -1392 . DOI: 10.13683/j.wph.2022.11.001
Xiu WANG, Xuefang YAO, Jinxi DING. Analysis of different modes of early resolution mechanism of patent disputes for biologics[J]. World Clinical Drug, 2022 , 43 (11) : 1387 -1392 . DOI: 10.13683/j.wph.2022.11.001
Year 2022 volume 43 Issue 11
11
2
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.11.001
  • Receive Date:2022-03-08
  • Online Date:2026-11-18
  • Published:2022-11-10
Article Data
Affiliations
History
  • Received:2022-03-08
Affiliations
    1.School of International Pharmaceutical Business, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
    2.School of Health Economics and Management, Jiangsu Nanjing University of Chinese Medicine, Nanjing 210023, Jiangsu Province, China
    3.Pharmaceutical Market Access Policy Research Center, China Pharmaceutical University, Nanjing 211198, Jiangsu Province, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.11.001
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT